Premium
The sustained release of LH · RH agonist from LH · RH agonist‐polymer composite in patients with prostatic cancer
Author(s) -
Imai Kyoichi,
Yamanaka Hidetoshi,
Yuasa Hisako,
Yoshida Masaro,
Asano Masaharu,
Kaetu Isao,
Yamazaki Iwao,
Suzuki Keiji
Publication year - 1986
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.2990080404
Subject(s) - agonist , medicine , luteinizing hormone , hormone , testosterone (patch) , endocrinology , cancer , prostate cancer , urology , chemistry , receptor
Luteinizing hormone‐releasing hormone (LH·RH) agonist can be administered daily to patients with prostatic cancer with resulting clinical efficacy. A sustained drug release formulation of an LH·RH agonist, (D‐Leu 6 )‐des Gly‐NH 2 10 ‐LH·RH ethylamide (leuprolide)‐vinyl polymer composite, was prepared by means of radiation‐induced polymerization under a supercooled state. The sustained release of leuprolide from subcutaneously implanted leuprolide‐vinyl polymer composite (14 mm in diameter and 4 mm in thickness) was obtained over a period of several months in five patients with prostatic cancer. Serum testosterone levels began to decrease on the tenth day, fell below 1 ng/ml after three weeks of implantation, and thereafter remained at the castration level until removal of the polymer composite. Clinical improvement was associated with serum hormonal changes, and support this as a novel and superior method of administration of LH·RH agonist.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom